Stock Movers: Lennar, VERV, T-Mobile (Podcast)

Lennar (LEN) is up despite a miss on new orders, driven by better-than-expected gross margins, reassuring investors according to RBC Capital Markets. Sunrun (RUN) shares are declining after KeyBanc Capital Markets downgraded the stock to underweight. Verve Therapeutics (VERV) is surging following reports of advanced acquisition talks with Eli Lilly (LLY) for a potential $1.3 billion deal, while Eli Lilly is lower on the M&A news. T-Mobile (TMUS) is sliding after SoftBank raised approximately $4.8 billion through the sale of 21.5 million shares at a 3% discount.

Analysis

The market is reacting to several distinct company-specific events. Lennar (LEN) shares are experiencing a slight uptick, primarily driven by better-than-expected gross margins which, according to RBC Capital Markets, reassured investors despite a miss on new orders outlook. Analysts like Mike Dahl noted Lennar's gross margin percentage was better than feared and its guidance for a flat quarter-on-quarter gross margin percentage was an upside surprise, even as second-quarter adjusted EPS missed consensus due to higher SG&A expenses and lower average selling prices, as highlighted by Barclays. Conversely, Sunrun (RUN) shares are declining in premarket trading following a downgrade to underweight from sector weight by KeyBanc Capital Markets analyst Sophie Karp; notably, this analyst's prior recommendations on Sunrun yielded a 0% return over the past year, while the stock itself returned negative 27%. Verve Therapeutics (VERV) is seeing a significant surge after a Financial Times report indicated Eli Lilly (LLY) is in advanced discussions to acquire the gene-editing startup for up to $1.3 billion, with nearly $1 billion upfront and $300 million tied to milestones. Consequently, Eli Lilly's shares are trading lower on this M&A news. T-Mobile (TMUS) shares are also under pressure, sliding after SoftBank executed a substantial $4.8 billion sale of 21.5 million T-Mobile shares at $224 each, representing a 3% discount to the previous closing price and marking the largest US share sale since February. The overall market sentiment reflected in these movements is mixed, with significant positive catalysts for VERV being offset by negative pressures on RUN, LLY, and TMUS.

Key Decisions for Investors

• For Lennar, investors should monitor upcoming new order trends and margin sustainability, as the strong gross margin performance is currently offsetting concerns from softer order outlook and higher operating expenses.
• Investors in Sunrun should critically assess the rationale behind KeyBanc's downgrade and the company's fundamental outlook, considering the stock's recent underperformance and the analyst's track record.
• Verve Therapeutics shareholders might consider realizing some gains given the substantial acquisition premium reported, while Eli Lilly investors should evaluate the strategic implications and financial dilution from the potential $1.3 billion acquisition.
• T-Mobile investors should observe if the share price stabilizes post-SoftBank's discounted large block sale, as this could present a buying opportunity if fundamentals remain unchanged by the technical selling pressure.